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Non-CG DNA methylation is a biomarker
for assessing endodermal differentiation capacity
in pluripotent stem cells
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Lars A¨hrlund-Richter7, Nessa Carey8, Ludovic Vallier4,6, Anne C. Ferguson-Smith3 & Stephan Beck1
Non-CG methylation is an unexplored epigenetic hallmark of pluripotent stem cells. Here we
report that a reduction in non-CG methylation is associated with impaired differentiation
capacity into endodermal lineages. Genome-wide analysis of 2,670 non-CG sites in a
discovery cohort of 25 phenotyped human induced pluripotent stem cell (hiPSC) lines
revealed unidirectional loss (Db¼ 13%, Po7.4 104) of non-CG methylation that correctly
identiﬁes endodermal differentiation capacity in 23 out of 25 (92%) hiPSC lines. Translation
into a simpliﬁed assay of only nine non-CG sites maintains predictive power in the discovery
cohort (Db¼ 23%, Po9.1 106) and correctly identiﬁes endodermal differentiation
capacity in nine out of ten pluripotent stem cell lines in an independent replication cohort
consisting of hiPSCs reprogrammed from different cell types and different delivery systems,
as well as human embryonic stem cell (hESC) lines. This ﬁnding infers non-CG methylation at
these sites as a biomarker when assessing endodermal differentiation capacity as a readout.
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on-CG DNA methylation is an epigenetic hallmark of
mammalian pluripotent stem cells1, which is gradually
lost on cell fate speciﬁcation2,3. The occurrence of
non-CG methylation is predominantly catalysed by DNMT3A
and DNMT3B in cooperation with DNMT3L2–4 and was ﬁrst
described in embryonic stem cells; however, its prevalence and
genomic localization has only been established recently5,6. Unlike
patterns of CG methylation where the majority of cytosines are
methylated6–8 and have been both extensively studied9–12 and
reviewed13–15, cytosines at non-CG dinucleotides in pluripotent
stem cell populations are only partially methylated and less well
studied4,6,8,16. We hypothesized that quantitative variation in
non-CG methylation may reﬂect pluripotent stem cell-speciﬁc
phenotypes and thus be suitable as a biomarker capable of
predicting differentiation capacity, complementing existing
methods such as PluriTest17 (which uses gene expression data)
and Scorecard9 (which uses CpG methylation and gene
expression data). Identiﬁcation of a biomarker solely based on
few non-CG sites would thus constitute an alternative. The
importance of discovering robust and easy-to-assay biomarkers is
that time-consuming and costly cell-based phenotyping measures
can be reduced, while simultaneously offering improvements in
large-scale assessment of human induced pluripotent stem cell
(hiPSC) lines for clinical utility and therapeutic applications.
Using a two-stage design we report here that pluripotent stem
cells with an impaired differentiation capacity for endodermal
lineages exhibit reduced DNA methylation at non-CG dinucleo-
tides targeted by the Illumina 450K array. This ﬁnding infers non-
CG methylation can be used as a biomarker for assessing
endodermal differentiation capacity.
Results
Differentiation capacity in pluripotent stem cell lines. We used
a two-stage design consisting of a discovery cohort of 25 hiPSC
lines, and a replication cohort of 7 hiPSC lines from the HipSci
study (http://www.hipsci.org) and 3 human embryonic stem cell
(hESC) lines (see Supplementary Table 1). In the discovery
cohort, we analysed hiPSC lines derived from a range of differ-
entiated somatic cells (dermal ﬁbroblasts (N¼ 20), foreskin
ﬁbroblasts (N¼ 1), endothelial precursor cells (N¼ 2) and
endothelial progenitor cells (N¼ 2)) obtained from seven unre-
lated individuals and two monozygotic twins. These hiPSC lines
were derived using OCT4, SOX2, KLF4 and c-MYC (OSKM)
reprogramming factors delivered using two virus-based vectors
(retrovirus (N¼ 23) and Sendai virus (N¼ 2)). In the replication
cohort, we extended the source of pluripotent stem cells to
include hESCs as well as diversifying the range of donor cell types
and OSKM delivery methods from which hiPSC lines were
derived; donor cells included erythroblasts (N¼ 4) and dermal
ﬁbroblasts (N¼ 3) obtained from ﬁve unrelated individuals, and
OSKM delivery systems included a DNA-based vector (episomal
(N¼ 3)) in addition to a virus-based vector (Sendai virus
(N¼ 4)); conﬁrmation of pluripotency, differentiation protocol
and differentiation capacity scoring are detailed in Methods. For
the hiPSCs used in the discovery cohort and hESC lines in the
replication cohort, we obtained multiple DNA extracts from
independent cells of the same plate (median N¼ 6), to control for
cell line variation (Supplementary Fig. 1); for the hiPSC lines in
the replication cohort, we obtained only single DNA extracts per
plate. All hiPSC lines in the discovery and replication cohorts
fulﬁlled criteria for pluripotency18: this was conﬁrmed by gene
expression and immunostaining for the core transcriptional
network of pluripotency markers and teratoma formation
when introduced into immunocompromised mice (see Methods
and Supplementary Figs 2–8). Despite fulﬁlling criteria for
pluripotency and controlling for uniform cell-plating densities,
there were marked differences in their differentiation capacities.
Speciﬁcally, a number of hiPSC lines showed impaired efﬁciency
to differentiate into the endoderm lineage leading us to categorize
hiPSC lines as either low or high endodermal differentiation
capacity (LDC and HDC, respectively).
DNA methylation age in pluripotent stem cell lines. We derived
methylation levels (b, the methylated fraction of cells analysed)
for 2,676 autosomal CpH sites (H¼A, T, C) at single base-pair
resolution using Illumina Inﬁnium HumanMethylation450
BeadChips (‘Illumina 450K BeadChips’). Where multiple DNA
extracts from independent cells of the same plate were available,
b-values were averaged. To ensure the abundant non-CG
methylation signal in pluripotent stem cells was not due to
incomplete bisulﬁte conversion, we conducted a number of
control experiments (see Methods and Supplementary Figs 9–13).
As an additional quality control measure, we computed DNA
methylation age (‘DNAm age’) using a subset of CpG probes on
the Illumina 450K BeadChip19. As embryonic stem cells are of
prenatal origin, we expect pluripotent cells to exhibit ‘negative
age’. Reassuringly, 150 of 161 (93%) pluripotent clones exhibited
negative age and none exceeded þ 0.5 years. There was no
signiﬁcant difference in DNAm age between HDC and LDC
pluripotent lines (mean DNAm age:  0.51 (HDC) versus  0.36
(LDC)). DNAm age for the available donor cell lines consistently
exceeded 18 years, conﬁrming the adult origin of each donor cell
line (Supplementary Fig. 14).
Promoter DNA methylation in pluripotent stem cells. We also
compared promoter methylation of our samples with the
‘Reference Corridor’ proposed by Bock et al.9. Following LiftOver
of promoter coordinates from hg18 to hg19, we derived a
consensus set of 14,820 promoters where at least one probe of the
Illumina 450K BeadChip overlapped; this consensus set of
promoters was represented by 109,109 CpG probes. As
Reference Corridor estimates were derived using Reduced
Representation Bisulﬁte Sequencing (RRBS), there was, on
average, more than four times the number of CpGs assayed per
promoter compared with Illumina 450K BeadChips; for this
reason we estimated promoter methylation in this cohort of
pluripotent stem cells using the median b-value, as the median is
less sensitive to outliers. However, despite the use of different
technologies we found 76.8% of all DNA methylation estimates
for this cohort fell within the bounds of the Reference Corridor
(Supplementary Fig. 15a). Curiously, the Reference Corridors of
1,734 (11.7%) promoters failed to capture any corresponding
Illumina 450K BeadChip estimates; Reference Corridors for these
promoters were characterized by intermediate methylation and
were mainly marked by a shift towards unmethylated status in
this cohort (Supplementary Fig. 15b). All coefﬁcients of variation
(CVs) at each of these promoters were o1 in this cohort,
indicating stable methylation status at each promoter.
Furthermore, many Illumina 450K BeadChip estimates only
narrowly missed being captured in the Reference Corridor:
almost a quarter (24%) of methylation estimates were within 10%
of a Reference Corridor threshold and nearly half (48%) were
o20%—magnitudes possibly attributable to the different
technologies being compared.
Non-CG methylation in pluripotent stem cell lines. To identify
methylation variable positions (MVPs) associated with impaired
endodermal differentiation capacity, we applied a false discovery
rate of 0.05. As previously deﬁned20, MVPs are referred to as
hyper- or hypo-MVPs when directionality towards differential
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hyper- or hypomethylation has been ascertained. Nearly all sites
tested (2,564 or 96%) were signiﬁcantly associated and all were
hyper-MVPs in HDC hiPSC lines compared with LDC hiPSC
lines; a ﬁnding not due to technical confounders (Supplementary
Fig. 16). Aggregating DNA methylation across all non-CG sites
(bmean), we found LDC and HDC hiPSC lines were characterized
by 37% (95% conﬁdence interval (CI)¼ 31–43%) and 50%
(95% CI¼ 47–52%) non-CG DNA methylation, respectively.
Mean levels of non-CG DNA methylation were not associated
with passage number (Pearson’s r¼ 0.52, P¼ 0.28; Supple-
mentary Fig. 17), whereas correlations of non-CG DNA
methylation proﬁles between pluripotent stem cell lines were
high (average r¼ 0.903) and CVs across cell lines at individual
loci were low (average CV¼ 0.49), leading us to infer that the
stability of non-CG methylation is actively maintained at this
subset of non-CG loci tested. Importantly, the difference in mean
non-CG methylation levels between LDC and HDC hiPSC lines
(Dbmean¼ 13% (95% CI¼ 6–19%); Fig. 1) was signiﬁcant using
both conventional statistical tests (Po7.4 10 4, two sample
t-test) and permutation testing (empirical P¼ 1.5 10 4). To
test whether overall CpG methylation levels were affected in the
same way, we performed 100,000 Monte Carlo simulations using
2,676 randomly sampled CpG probes: we found Dbmean between
HDC and LDC groups never exceeded 0.005, which intensiﬁes the
importance of non-CG DNA methylation loss in LDC hiPSCs.
Furthermore, the lack of a global CpG methylation difference
between HDC and LDC groups was observed when solely
methylated (that is, b480%) CpG probes were randomly
sampled, which more accurately reﬂects the true genomic
distribution of CpG methylation. Lastly, the direction and
magnitude of the non-CG effect was independent of 6-bp
sequence motif surrounding the non-CG locus (Supplementary
Fig. 18).
Gene expression of key (de)methylation genes. We next inves-
tigated the effect of DNA (de)methylation machinery on non-CG
DNA methylation levels. We proﬁled gene expression of DNMT1,
DNMT3A, DNMT3B and DNMT3L, as well as TET1 by quanti-
tative reverse transcriptase–PCR (qRT–PCR) in the discovery
cohort. Of these genes, only DNMT3B showed signiﬁcantly
different gene expression between LDC and HDC hiPSC
lines (Supplementary Fig. 19a). We also analysed expression
of the DNMT genes and TET1 in different passages of the same
cell line (FF-iPSC-832-44-R) and found it was positively
correlated (r¼ 0.901–0.984), although least strongly in DNMT3B
(r¼ 0.825) (Supplementary Fig. 19b). However, there were no
signiﬁcant differences in CpG methylation between LDC and
HDC hiPSCs at the promoters of these genes (Supplementary
Fig. 20).
Epigenetic memory analyses. To conﬁrm that non-CG
methylation differences between LDC and HDC hiPSCs was not
driven by epigenetic memory; for example, predicated by non-CG
methylation differences at the donor cell level, we focused our
analysis on hiPSCs with matched donor cells. First, donor cells
giving rise to both LDC and HDC hiPSC lines (subsequently
referred to as ‘LDC donors’ and ‘HDC donors’) were character-
ized by notably low and equal levels of non-CG methylation
(bmean: 8% (95% CI¼ 6–10%); Dbmean¼NS). Non-CG methyla-
tion in donors is not at or close to 0%, because the dynamic range
of the array is reduced rather than issues of incomplete bisulﬁte
conversion. Second, there were no signiﬁcant MVPs between
LDC and HDC donors. Third, Dbmean between donors and hiPSC
lines were notably higher for the HDC group compared with the
LDC group (Dbmean: 42% versus 29%, respectively), indicating
that LDC hiPSCs are more refractory to the acquisition of non-
CG methylation (Supplementary Fig. 21). In summary, LDC
hiPSCs are characterized by hypomethylation at the majority of
non-CG sites assayed on the Illumina 450K BeadChip, which is
not predicted by the baseline non-CG proﬁle of the donor cell.
Polymorphism analyses. We next investigated whether the
observed differences in non-CG methylation between LDC and
HDC hiPSCs were due to the presence of polymorphisms. We
mapped all non-CG sites to data from the 1,000 Genomes
Project21 and found evidence of genetic variation at just four
(0.1%) loci, which conﬁrms that a reduction in non-CG
methylation in LDC samples is not due to the loss of
methylatable cytosines. We next searched for polymorphisms in
the entire probe and found only 61 (2.3%) non-CG probes were
potentially affected by polymorphism within 10 bp of the 30-end
of the probe, which rules out confounding by technical factors22.
Non-CG methylation as a biomarker. Unsupervised hierarchical
clustering using all 2,564 signiﬁcant non-CG probes revealed a
largely unequivocal separation of LDC, HDC and donor cell lines
(Fig. 2 and Supplementary Fig. 22). Consistent with previous
ﬁndings9,23, donor cells and hiPSCs formed separate clades, in
our case, illustrating a clear inﬂuence of non-CG methylation in
the pluripotency phenotype. However, more profound was the
correct classiﬁcation of hiPSC lines (23 of 25, or 92%) into LDC
and HDC clades.
For validation and translation into a more simpliﬁed assay, we
selected nine highly signiﬁcant MVPs and subjected them to
bisulﬁte pyrosequencing. Methylation levels obtained using this
independent platform showed high agreement with the Illumina
450K BeadChip (Pearson’s r¼ 0.92, P¼ 2.2 10 16;
Supplementary Fig. 23) and conﬁrmed signiﬁcant association of
each tested MVP (Supplementary Table 2). Crucially, this subset
of MVPs maintains separation between LDC and HDC hiPSC
lines, irrespective of analysis platform (Illumina: Dbmean¼ 23%
(95% CI¼ 15–31%, Po9.1.0 10 6); bisulﬁte pyrosequencing
Dbmean¼ 18% (95% CI¼ 12–24%, Po7.5 10 6): two sample
t-test; Fig. 3a).
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Figure 1 | Non-CG methylation is prevalent but reduced in LDC hiPSCs.
Density plot illustrating the difference in non-CG methylation proﬁles
between low-differentiation capacity (LDC; red line) and high-
differentiation capacity (HDC; blue line) hiPSCs. The difference in mean
methylation (Db) was large (13%) and signiﬁcant (Po7.4 104). For
comparison, non-CG proﬁles are plotted for donor cell lines giving rise to
LDC (grey line) and HDC (orange line) hiPSCs; the difference between
these donor cell lines was not signiﬁcant.
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The predictive utility of the nine-probe non-CG methylation
assay to classify HDC and LDC status was borne out using a
replication cohort of ten additional pluripotent stem cell lines
comprising three hESC lines and seven hiPSC lines derived from
additional donor cell types (erythroblasts) and additional
reprogramming methods (episomal vector), grown in an
independent laboratory (see Supplementary Table 1). b-Values
for the nine-probe assay were derived from Illumina 450K
BeadChips, to ascertain the mean non-CG methylation for each
pluripotent stem cell line and thereby predict endodermal
differentiation capacity status; endodermal differentiation
capacity phenotying was performed independently and blindly.
We deﬁned the threshold for endodermal differentiation capacity
status (bmean¼ 45.8%) as the midpoint between LDC upper
(b¼ 40%) and HDC lower (b¼ 52%) 95% CIs of the mean
non-CG level of the nine-probe assay in the discovery cohort.
Using this threshold, we correctly identiﬁed the endodermal
differentiation capacity for nine out of ten (90%) pluripotent stem
cell lines (Fig. 3b). In summary, non-CG methylation is a
biomarker for stem cell endodermal differentiation capacity,
independent of reprogramming method, donor cell type and
source of pluripotent cell type (hiPSC and hESC).
Discussion
The derivation of hiPSCs from easily accessible tissue sources has
far reaching implications for the ﬁelds of drug screening and
development, as well as regenerative medicine24. However, a
number of challenges remain25. One pressing issue is the
identiﬁcation of molecular surrogates that predict the
differentiation capacity of an hiPSC to form all three embryonic
germ layers26. Although variability in differentiation capacity has
been attributed to tissue of origin effects9,23,27 and
reprogramming technologies28, variability still remains even
when these variables are kept constant. Although our results
are not immune to some degree of overﬁtting (our study design
used more samples in the discovery cohort than the replication
cohort), we do show that levels of DNA methylation at a subset of
non-CG dinucleotides can serve as a powerful unidirectional
biomarker capable of distinguishing pluripotent lines of high and
low endodermal differentiation capacity.
Whether this ﬁnding extends to predict differentiation capacity
in other lineages remains an important question. We tried
exploring non-CG DNA methylation in eight pluripotent cell
lines (four ES lines and four hiPSC lines) with RRBS data4 and
corresponding lineage differentiation capacity information9;
however, we were unable to establish a positive correlation,
presumably because of insufﬁcient overlap between 450K- and
RRBS-derived non-CG data. Only ten non-CG loci overlap, none
of which encompass the biomarker proposed here. This is
important because genomic localization matters: although
de novo methyltransferase activity in pluripotent stem cells is
widespread, it has been proposed to be recruited to speciﬁc loci,
in particular those exhibiting high levels of methylation4; of
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Figure 2 | Non-CG DNA methylation proﬁles can separate LDC from HDC hiPSCs. Unsupervised hierarchical clustering using non-CG methylation data
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particular note, the non-CG loci assayed on the Illumina 450K
array are enriched for regions of H3K36me3 compared with the
RRBS loci. Furthermore, unlike Ziller et al.4 who found only
modest correlations (average r¼ 0.35) between pluripotent stem
cell lines and high CVs at non-CG loci (average CV¼ 3.0), we
found high correlations (average r¼ 0.903) and low CVs (average
CV¼ 0.49)—values that are more akin to those measured at
CpGs4. It is therefore feasible that the loci assayed in this study
represent putatively more functional non-CG targets with respect
to differentiation capacity. Second, the different phenotyping
methods employed in Bock et al.9 further complicates a direct
comparison with our study.
The functional consequence of non-CG methylation is
currently unclear but its presence can directly inhibit the binding
of speciﬁcity protein 1 (Sp1)29. Sp1 contributes to the
maintenance of methylation-free CpG islands30 and can
increase promoter activity31, as well as regulating a variety of
cellular processes including tissue-speciﬁc transcriptional
activity32, cell differentiation and chromatin remodelling33.
Experiments carried out by Clark et al.29 have shown
that methylation of the internal CpG site at the consensus
Sp1-binding site core (50-CCGCCC-30) was able to inhibit Sp1
binding by up to 20% and when the 50-non-CG site was
methylated, Sp1 binding was inhibited by up to 40%. However,
when both sites were methylated, Sp1 binding was virtually
blocked (95% inhibition)29. In the case of Sp1, it is therefore
feasible that non-CG methylation may act as a pluripotent stem
cell-speciﬁc mechanism to keep some constitutively unmethylated
genomic regions (for example, CpG islands) methylated.
Although the mechanistic actions of non-CG DNA methyla-
tion on differentiation are unknown, our results offer a novel, fast
and economic approach for large-scale assessment of hiPSC lines
for clinical utility and therapeutic applications. However, future
work should include data mining for other putative regulatory
sites affected by non-CG DNA methylation and testing the
functional effect of occluded DNA-binding proteins in quantita-
tive knockdown paradigms to simulate the intermediately
methylated states seen at non-CG loci in pluripotent stem cells.
Methods
Cell lines. A total of 32 hiPSC lines, 3 hES cell lines and 7 primary ﬁbroblast cell
lines were included in the study (Supplementary Table 1). All hiPSC lines
used in the study were either derived from ﬁbroblasts obtained from the Coriell
Biodepositiory or derived from tissues listed in Supplementary Table 1 obtained
from patients who provided written signed consent ethics approval from the
Hertfordshire Ethical Committee (08/H0311/201). All cell lines were negative for
mycoplasma contamination.
qRT–PCR analysis for cell phenotyping. Total RNA was obtained using
GenElute Mammalian Total RNA Miniprep Kit (Sigma Aldrich) according to
manufacturer’s recommendation, followed by complementary DNA synthesis
using standard protocols. Brieﬂy, cDNA was synthesized using Superscript II
Reverse Transcriptase (Invitrogen) kit with 0.5 mg of total RNA input. qRT–PCR
was performed using Sensi Mix Sybr Low Rox Kit (Bioline) then denatured at 94 C
for 5min and cycled at 94 C for 30 s, 60 C for 30 s and 72 C for 30 s for 40 cycles,
followed by a ﬁnal extension at 72 C for 10min, which was performed using a
Stratagene Mx3005P thermal cycler machine. qRT–PCR results were normalized to
porphobilinogen deaminase. Primer sequences are presented in Supplementary
Table 3.
Immunostaining. hESCs, hiPSCs and their differentiated derivatives were ﬁxed for
20min at 4 C in 4% paraformaldehyde and then washed three times in PBS. Cells
were then incubated for 20min at room temperature in PBS containing 10%
donkey serum (Serotec) and 0.1% Triton-X (Sigma). Cells were subsequently
incubated overnight at 4 C with the following primary antibodies diluted in
1% donkey serum in PBS (OCT4 1:100 (Santa Cruz; P/N: SC-8628X), NANOG,
SOX2, SOX1, SOX17, FOXA2 1:100 (R&D Biosystems); P/Ns: AF1997, AF2018,
AF3369, AF1924 and AF2400, respectively)). Cells were then washed three times in
PBS and incubated with Texas Red or ﬂuorescein isothiocyanate-conjugated
Donkey anti-mouse IgG (1:1,000, Invitrogen; P/N: A21202) or Donkey anti-rabbit
IgG (1:1,000, Invitrogen; P/N: A10042), or Donkey anti-goat IgG (1:1,000,
Invitrogen; P/N: A11057) for 2 h at room temperature. The cells were washed three
times in PBS (with Hoechst, Sigma-Aldrich, 1:10,000 in the ﬁrst wash to stain the
nuclei blue). Images were obtained with Zeiss Axiovert 200M microscope with
AxioVision Rel 4.7 software (Carl Zeiss, Jena, Germany).
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Figure 3 | Translation and simpliﬁcation of a discriminative non-CG assay. We selected 9 of the top 200 non-CG MVPs and aggregated methylation
levels for the two hiPSC phenotypes. (a) Separation between the two hiPSC phenotypes was maintained and independently validated with bisulﬁte
pyrosequencing. Mean methylation levels are indicated by cross-hairs; P-values derived by two sample t-tests. (b) Sample-speciﬁc deviations from an
endodermal differentiation capacity threshold in the discovery and replication cohorts. The endodermal differentiation capacity threshold (bmean¼45.8%)
is deﬁned as the midpoint between the upper (LDC) and lower (HDC) 95% CIs of mean non-CG levels in the discovery cohort for the nine-probe assay.
This threshold correctly identiﬁes 23 of 25 hiPSC lines in the discovery cohort; this ﬁnding was replicated in 3 hESC lines and 7 hiPSC lines derived from
additional donor cell types and additional reprogramming methods from additional labs. Green bars, HDC (predicted); red bars, LDC (predicted); blue
sample labels, HDC (phenotyped); red sample labels, LDC (phenotyped).
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Flow cytometry. Cells were washed twice in PBS and then incubated for 20min at
37 C with cell dissociation buffer (Invitrogen). Cells were dissociated by gentle
pipetting and resuspended at B0.1–1 105 cells per ml in PBS plus 3% normal
goat serum containing 0.1% azide (Serotec). Cells were then ﬁxed for 20min at 4 C
in 4% paraformaldehyde and then washed three times in PBS. Cells were then
incubated for 2 h at room temperature with primary antibody (OCT4 (1:100; Santa
Cruz; P/N: SC-8628X), CXCR4 (1:100; R&D Biosystems; P/N: MAB173) and
SOX17 (1:100; R&D Biosystems; P/N: AF1924)) or mouse IgG isotype control
(1:100; BD Biosciences-Pharmigen; P/N: 555749). Cells were then washed three
times in PBSþ 3% normal goat serum containing 0.1% azide and then incubated
with secondary antibodies for 2 h at room temperature. Unbound secondary
antibody was removed by three washes in PBS. Cells were analysed in a Beckman
Coulter CyAn ADP ﬂow cytometer (Beckman Coulter, High Wycombe, UK).
Teratoma assay. hiPSCs were harvested mechanically immediately before
implantation, andB1 105 cells were inoculated beneath the testicular capsule of 6-
to 8-week-old C.B. 17/GbmsTac-scid-bgDF N7 male mice (Taconic M&B) housed
and maintained at 20–24 C, 50% room humidity, in a 14-h light and 10-h dark cycle
with food and water ad libitum. The mice were killed after 60 days and the injected
testes were cut into equal pieces using a razor blade. The material was ﬁxed overnight
in 4% neutral buffered formaldehyde and dehydrated through a graded series of
alcohols to xylene. The tissue was embedded in parafﬁn and serially sectioned at
5mm, followed by haematoxylin and eosin staining and characterization. A human
origin of the selected areas was veriﬁed by ﬂuorescent in situ hybridization (human-
speciﬁc probes, CEP XY; Vysis Inc.). The experiments were performed with per-
mission from The Stockholm North Ethical Committee on Animal Experiments
(Stockholm, Sweden; permission number: N105/07).
In vitro differentiation. Endoderm differentiation has been described as follows34.
Brieﬂy, hESCs and hiPSCs were harvested with dispase (1mgml 1) for 1 h and then
seeded in gelatinized fetal bovine serum-coated plates in chemically deﬁned media
(CDM) supplemented with Activin A and ﬁbroblast growth factor 2 (FGF2) for 24 h.
To obtain endodermal progenitors, cells were grown in CDM with Polyvinyl Alcohol
supplemented with Activin A (100ngml 1), ﬁbroblast growth factor 2 (FGF2)
(20 ngml 1), bone morphogenetic factor 4 (BMP4) (10 ngml 1) and LY294002
(10mM) for 3 days. For neuroectoderm differentiation, cells were grown in CDM
with polyvinyl alcohol supplemented with SB431542 (10mM), FGF2 (12 ngml 1)
and Noggin (200ngml 1) for 10 days. For BMP4 treatment, cells were grown in
CDM with bovine serum albumin supplemented with BMP4 (10 ngml 1) and
SB431542 (10mM) for 10 days. For pancreatic differentiation, human pluripotent
stem cells were differentiated into endoderm using CDM supplemented with Activin
A (100ngml 1), BMP4 (10 ngml 1; R&D Systems), basic ﬁbroblast growth factor
(20 ngml 1) and LY294002 (10mM; Promega) for 3 days. After deﬁnitive
endoderm-differentiation stage, cells were cultured in Advanced DMEM
supplemented with BSA, SB-431542 (10mM; Tocris), ﬁbroblast growth factor 10
(FGF10) (50ngml 1; AutogenBioclear), all-trans retinoid acid (2mM; Sigma) and
Noggin (150ngml 1; R&D Systems) for 3 days. After that, cells were cultured in
Advanced DMEMþ human FGF10 (50ngml 1; AutogenBioclear), all-trans
retinoid acid (2mM; Sigma), KAAD-cyclopamine (0.25M; Toronto Research
Chemicals) and Noggin (150ngml 1; R&D Systems) for 3 days. Finally, the cells
were cultured in human KGF (50 ngml 1; R&D Systems) for 3 days. For
maturation of pancreatic progenitors, cells were grown in Advanced DMEMþ 1%
vol/vol B27 and DAPT (1mM) for 3 days and for 3 additional days in Advanced
DMEMþ 1% vol/vol B27. More details can be found in ref 35.
Conﬁrmation of pluripotency. Pluripotency was assessed in a number of ways.
First, we analysed activity of the core pluripotency markers (OCT4, NANOG and
SOX2 for hiPSCs in the discovery cohort and hESCs in the replication cohort, and
OCT4 only for hiPSCs in the replication cohort) in undifferentiated human plur-
ipotent stem cells (hPSCs) using qRT–PCR; results are presented in Supplementary
Fig. 2a,b. Second, we veriﬁed the absence of reprogramming transgenes by endo-
genous and exogenous gene expression analysis by qRT–PCR of OCT4, SOX2, KLF4
and cMYC; results for the discovery cohort are presented in Supplementary Fig. 3.
Third, we conﬁrmed homogeneity of cells in a selection of discovery cohort hiPSCs
by immunoﬂuorescence of OCT4, NANOG and SOX2 (Supplementary Fig. 4a), and
ﬂow cytometry of OCT4 (Supplementary Fig. 4b). Fourth, we assessed the ability of
differentiated hPSCs to produce progenitors of three germ layers. Gene expression
analysis of SOX2 and SOX1 (neuroectoderm), and SOX7 and HAND1 (primitive
endoderm and extraembryonic ectoderm markers) was performed in the discovery
cohort; results are presented in Supplementary Fig. 5a,b. Immunostaining for SOX2
and SOX1 was performed for a selection of the discovery cohort; results are
presented in Supplementary Fig. 5c.
Endodermal differentiation capacity scoring. We categorized hPSCs as HDC if
they generated endodermal cells expressing the deﬁnitive endoderm markers
SOX17, FOXA2 and CXCR4, and the primitive streak markers EOMES and MIXL1.
For the hiPSCs in the discovery cohort and hESCs in the replication cohort, we
used qRT–PCR for gene expression analysis of SOX17, FOXA2, EOMES and
MIXL1 (Supplementary Fig. 6a). For the hiPSCs in the replication cohort, we used
qRT–PCR for gene expression analysis of SOX17 and CXCR4 (Supplementary
Fig. 6b). For a selection of hiPSCs from the discovery cohort, we used immunos-
taining for SOX17, FOXA2 and EOMES (Supplementary Fig. 6c), and ﬂow
cytometry for CXCR4 (Supplementary Fig. 6d). For the replication cohort, we used
ﬂow cytometry for SOX17 and CXCR4 (Supplementary Fig. 6e). Unlike HDC lines,
LDC lines showed decreased expression of the endodermal markers, generated
a low yield of SOX17- and FOXA2-positive cells, and exhibited low yields of
CXCR4- and/or SOX17-expressing cells.
Characterization of differentiation capacity. To further study the limited
capacity to differentiate into endoderm, ﬁve LDC and one HDC hiPSC lines were
induced to generate pancreatic progenitors using a combination of retinoic acid,
NOGGIN, FGF10 and inhibitor of NODAL signalling. We measured the expression
of PDX1 (a transcription factor that is expressed during pancreatic development)
and hormonal markers such as Glucagon and Insulin, after 18 days of differ-
entiation. We found that these genes were not upregulated in LDC lines, whereas
the expression levels were high in the HDC line consistent with LDC lines being
refractory to endodermal differentiation (Supplementary Fig. 7a–c). We also
performed teratoma assays on 2 LDC and 1 HDC hiPSC line to conﬁrm a quan-
titative reduction in the yield of endodermal progenitors in LDC hiPSCs compared
with HDC hiPSCs (see ref. 36 and Supplementary Table 4). The ﬁnal status of
endodermal differentiation capacity status for each pluripotent cell line is presented
in Supplementary Table 1. In summary, hPSC lines were categorized as LDC if they
produced o50% Sox17- or CXCR4-expressing cells as revealed by FACS; HDC
hPSC lines produced 460% expressing cells.
DNA preparation. Genomic DNA was extracted from cells using GenElute
Mammalian DNA Miniprep Kit (Sigma) or AllPrep DNA/RNA Mini Kit (Qiagen)
according to the manufacturer’s protocol. DNA purity and quantity were checked by
spectrophotometry (NanoDrop ND-1000, Thermo Scientiﬁc); DNA quality (frag-
ment integrity) was assessed using 1% tris-borate-EDTA agarose gels. Before bisulﬁte
conversion, DNA concentration was estimated by ﬂuorometry (Qubit 2.0, Life
Technologies) and 1mg DNA was bisulﬁte converted (EZ DNA Methylation Kit,
Zymo Research) in accordance with the manufacturer’s protocol with alternative
incubation conditions (that is, 16 cycles (95 C for 30 s, 50 C for 60min)).
DNA methylation proﬁling. Following bisulﬁte conversion quality control with
quantitative PCR (qPCR; see below), bisulﬁte-converted DNA extracts were
hybridized to Inﬁnium 450K BeadChips (Illumina) and scanned with iScan
(Illumina) in accordance with the manufacturer’s protocol. Following scanning,
raw data in the form of IDAT ﬁles were funnelled through the ChAMP analysis
pipeline37 implemented in R (http://www.R-project.org/). ChAMP is an integrated
workﬂow that ues a number of Bioconductor packages. Within ChAMP, IDAT ﬁles
were loaded and normalized using minﬁ38. Probes with low detection metrics
(Po0.01) in at least one DNA extract were excluded. Raw (non-normalized)
methylation levels (b, the methylated fraction of cells assayed) were calculated
(SignalMeth/(SignalMethþ SignalUnmeth)) for each DNA extract in the discovery and
replication cohorts (N¼ 177þ 20). For samples with multiple technical replicates,
Euclidian distances between DNA extracts based on b were plotted in two-
dimensional space for single-nucleotide polymorphism (rs#) probes; two outliers
that misclustered were identiﬁed by observation with the naked eye and were
removed from further analysis. For the remaining DNA extracts (N¼ 195), signal
intensities for all probes (including 834 quality control probes used to assess
bisulﬁte conversion, extension, hybridization, negative controls, speciﬁcity, staining
and target removal) were normalized using the subset-quantile within array
normalization SWAN39 method. Data from the quality control probes were
combined with coded systematic information (batch, array position and slide) and
phenotypic information (sex, cell type and cell line) for singular value
decomposition40 analysis to identify confounding factors. Singular value
decomposition analysis indicated that substantial components of DNA methylation
were correlated with biological factors but not with technical factors
(Supplementary Fig. 12). All empirical analyses were performed using normalized
b-values with the exception of statistical testing, to identify methylation variable
positions (MVPs); here, b-values were logit transformed into M-values to reduce
heteroscedascity41. Differences in M-values were tested for statistical signiﬁcance
using moderated t-tests where sample variances were shrunk by computing
empirical Bayes posterior means using the limma package42, with multiple DNA
extracts appropriately speciﬁed. As samples contained a mixture of males and
females, we omitted probes mapping to chromosomes X and Y.
Bisulﬁte conversion quantity control. We controlled bisulﬁte conversion efﬁ-
ciency using ﬁve separate analyses. First, we used qPCR to amplify eight randomly
selected samples and four controls using two primer pairs (one for converted DNA
and the other for unconverted DNA; see Supplementary Fig. 5). Desulfonated and
puriﬁed products were quality controlled for bisulﬁte conversion using triplicate
qPCR reactions in a ﬁnal reaction volume of 12.5 ml (6.25 ml reaction buffer (MESA
Blue, Eurogentec), 0.625 ml primer pair (10 mM each; see below), 4.375ml water
and 1.25 ml DNA). qPCR conditions were as follows: 95 C for 5min, 40 cycles
(95 C for 15 s, 60 C for 60 s), meltcurve). Primers were designed for converted
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(F: 50-TGGTGATGGAGGAGGTTTAGTAAGT-30 , R: 50-AACCAATAAAACC
TACTCCTCCCTTAA-30) and unconverted (F: 50-TGGTGATGGAGGAGGC
TCAGCAAGT-30 , R: 50-AGCCAATGGGACCTGCTCCTCCCTTGA-30) DNA.
Second, we manually inspected b-plots. Capitalizing on the Illumina 450K
BeadChip’s probe design, we reasoned that incomplete bisulﬁte conversion would
not only artiﬁcially inﬂate non-CG estimates but would also disrupt the distribu-
tion (and detection rate) of CpG b-values (Supplementary Fig. 6). Third, we made
use of the inbuilt Illumina 450K BeadChip control probes. The Illumina 450K
BeadChip contains hundreds of control probes measured in each of its red and
green channels; from the green channel only, we extracted all 6 Inﬁnium I Assay
bisulﬁte conversion control probe intensities (3 converted (BIC1–3)þ 3 uncon-
verted (BIU1–3)) and the mean of the 613 negative control probe intensities (NI), to
derive an estimate of bisulﬁte conversion efﬁciency (Supplementary Fig. 7). Next,
we calculated background-adjusted Inﬁnium I Assay bisulﬁte conversion control
probe intensities:
Adj BIXi ¼ BIXi NI ð1Þ
where X is control probe design (converted/unconverted) and i is the probe
number (1–3). Bisulﬁte conversion efﬁciency was then calculated as:
Median Adj BIC1 3ð ÞP
Median Adj BIC1 3ð Þ; median Adj BIU1 3ð Þ½  ð2Þ
Fourth, to calibrate our bisulﬁte conversion efﬁciency estimates we proﬁled
whole-genome-ampliﬁed and subsequently in vitro-methylated (SssI methyl-
transferase) DNA on the Illumina 450K BeadChip in duplicate (Supplementary
Fig. 8). Finally, we tested two additional ultra-stringent bisulﬁte conversion
protocols using the H9 hESC line (Supplementary Fig. 9). As non-CG methylation
could be an artefact of incomplete or insufﬁcient bisulﬁte conversion, it has been
suggested that extra steps be performed. To assess the effect of these extra steps we
conducted duplicate reactions of the following conditions: (1) standard bisulﬁte
conversion thermal cycling conditions (employed in this study); (2) similar as in
(1) þ prior proteinase K and two rounds of phenol–chloroform extraction; (3)
similar as in (2)þ second round of bisulﬁte conversion.
Bisulﬁte pyrosequencing. One microgram of genomic DNA was bisulﬁte
converted (Imprint DNA Modiﬁcation Kit, Sigma Aldrich) according to the
manufacturer’s protocol. Puriﬁed samples were ampliﬁed by PCR carried out in a
ﬁnal reaction volume of 10 ml (250 nM forward and reverse primers (F and R, see
Supplementary Table 5), 0.25U Taq (HotStarTaq DNA Polymerase, Qiagen) and
0.2mM dNTPs). PCR conditions were as follows: 95 C for 15min, 40 cycles
(94 C for 30 s, 48 C for 30 s, 72 C for 30 s), 72 C for 5min. Single-strand PCR
products were puriﬁed (PyroMark Q96 Vacuum Prep Workstation, Qiagen).
Pyrosequencing was performed on a PyroMark Q96 MD (Qiagen) using PyroMark
Gold Q96 Reagents (Qiagen) and locus-speciﬁc pyrosequencing (PSQ) primers (see
Supplementary Table 5) in accordance with the manufacturer’s protocol. The
degree of methylation at a non-CG site was determined as a single-nucleotide
polymorphism by PyroMark MD software.
qRT–PCR for DNMTs and TET1 gene expression. Total RNA was extracted
from cells using TRI Reagent (Sigma Aldrich). Total RNA (0.5 mg) was reverse
transcribed using RevertAid H Minus Reverse Transcriptase (Thermo Scientiﬁc).
qRT–PCR reaction mixtures were prepared according to the manufacturer’s
recommendations using LightCycler 480 SYBR Green I Master (Roche). Reactions
were performed using LightCycler 480 II (Roche). Standard curves were generated
for each primer set and were used to calculate the relative quantity of each primer
set by the relative quantity of expression of reference gene. Primers were taken
from ref. 43 and are presented in Supplementary Table 6.
Bioinformatic analysis using published data sets. Bock et al.9: methylation
thresholds and data for the Reference Corridor of 16,383 promoters was
downloaded from the Supplementary Information section of the publication.
Genome assembly coordinates of these promoters were converted from NCBI/hg18
to GRCh37/hg19 using the LiftOver utility implemented in Galaxy44–46. Sixty-ﬁve
of 16,383 (0.4%) hg18 promoter coordinates could not be mapped to hg19.
Ziller et al.4: processed and scored non-CG methylation data from eight
hPSC lines (hES H1, hES H9, hES HUES1, hES HUES8, hiPS 17b, hiPS 27b, hiPS
27e and hiPS 29e) with Scorecard9 data were downloaded from Gene Expression
Omnibus (GSE27432). Genome assembly coordinates were converted from NCBI/
hg18 to GRCh37/hg19 using the LiftOver utility implemented in Galaxy44–46.
Depending on the sample, between 107 and 137 non-CG with hg18 loci could not
be mapped to hg19.
The intersect of genomic loci/regions between two or more data sets was
determined using the GenomicRanges47 package of Bioconductor and implemented
in R. Sequences for genomic regions was retrieved using UCSC hg19 from the
BSgenome package of Bioconductor and implemented in R. Sequence matching was
achieved using the Biostrings package of Bioconductor and implemented in R.
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